SUTRO BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.94 USD | +5.35% |
|
+15.20% | -8.16% |
Financials (USD)
| Sales 2024 * | 71.73M | Sales 2025 * | 60.34M | Capitalization | 322M |
|---|---|---|---|---|---|
| Net income 2024 * | -217M | Net income 2025 * | -260M | EV / Sales 2024 * | 2.2 x |
| Net cash position 2024 * | 164M | Net cash position 2025 * | 368M | EV / Sales 2025 * | -0.76 x |
| P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
-1.21
x | Employees | 302 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sutro Biopharma, Inc.
More recommendations
More press releases
More news
| 1 day | +5.35% | ||
| 1 week | +15.20% | ||
| Current month | +16.05% | ||
| 1 month | -22.59% | ||
| 3 months | -12.83% | ||
| 6 months | +46.47% | ||
| Current year | -8.16% |
1 week
3.35
4.01
1 month
3.305.28
Current year
3.206.13
1 year
2.016.13
3 years
2.0123.70
5 years
2.0128.30
10 years
2.0128.30
| Managers | Title | Age | Since |
|---|---|---|---|
William Newell
CEO | Chief Executive Officer | 66 | 09-01-13 |
Jane Chung
PSD | President | 53 | 21-08-08 |
Edward Albini
DFI | Director of Finance/CFO | 66 | 13-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Connie Matsui
CHM | Chairman | 70 | 19-06-23 |
James Panek
BRD | Director/Board Member | 71 | 20-01-06 |
Daniel Petree
BRD | Director/Board Member | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 9 M€ | +5.77% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 3.94 | +5.35% | 775,279 |
| 24-05-01 | 3.74 | +10.16% | 973,839 |
| 24-04-30 | 3.395 | -3.55% | 523,944 |
| 24-04-29 | 3.52 | +2.92% | 547,522 |
| 24-04-26 | 3.42 | 0.00% | 474,120 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotes
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.94
USD
Average target price
12.89
USD
Spread / Average Target
+227.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.16% | 322M | |
| -1.65% | 103B | |
| +6.75% | 101B | |
| +6.46% | 23.07B | |
| -12.60% | 22.23B | |
| -5.43% | 18.05B | |
| -39.98% | 17.18B | |
| -10.17% | 16.94B | |
| +6.12% | 14.07B | |
| +35.47% | 12.35B |
- Stock Market
- Equities
- STRO Stock
